메뉴 건너뛰기




Volumn 15, Issue 12, 2016, Pages 2825-2834

Mechanisms of resistance to antibody-drug conjugates

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY DRUG CONJUGATE; CARRIER PROTEIN; CELL RECEPTOR; TUMOR ANTIGEN; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; CYTOTOXIN; MONOCLONAL ANTIBODY;

EID: 85008401036     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-16-0408     Document Type: Review
Times cited : (128)

References (66)
  • 1
    • 79952284127 scopus 로고    scopus 로고
    • Hallmarks of cancer: The next generation
    • Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011;144:646-74.
    • (2011) Cell , vol.144 , pp. 646-674
    • Hanahan, D.1    Weinberg, R.A.2
  • 3
    • 67649886201 scopus 로고    scopus 로고
    • Potent antibody drug conjugates for cancer therapy
    • Senter PD. Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol 2009;13:235-44.
    • (2009) Curr Opin Chem Biol , vol.13 , pp. 235-244
    • Senter, P.D.1
  • 4
    • 84906874906 scopus 로고    scopus 로고
    • Ado-Trastuzumab emtansine (T-DM1): An antibodydrug conjugate (ADC) for HER2-positive breast cancer
    • Lambert JM, Chari RV. Ado-Trastuzumab emtansine (T-DM1): An antibodydrug conjugate (ADC) for HER2-positive breast cancer. J Med Chem 2014;57:6949-64.
    • (2014) J Med Chem , vol.57 , pp. 6949-6964
    • Lambert, J.M.1    Chari, R.V.2
  • 5
    • 84863688504 scopus 로고    scopus 로고
    • The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
    • Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 2012;30:631-7.
    • (2012) Nat Biotechnol , vol.30 , pp. 631-637
    • Senter, P.D.1    Sievers, E.L.2
  • 7
    • 84934444640 scopus 로고    scopus 로고
    • Antibody-drug conjugate (ADC) clinical pipeline: A review
    • Sassoon I, Blanc V. Antibody-drug conjugate (ADC) clinical pipeline: A review. Methods Mol Biol 2013;1045:1-27.
    • (2013) Methods Mol Biol , vol.1045 , pp. 1-27
    • Sassoon, I.1    Blanc, V.2
  • 8
    • 84963814117 scopus 로고    scopus 로고
    • Current approaches for ADME characterization of antibody-drug conjugates: An industry white paper
    • Kraynov E, Kamath AV, Walles M, Tarcsa E, Deslandes A, Iyer RA, et al. Current approaches for ADME characterization of antibody-drug conjugates: An industry white paper. Drug Metab Dispos 2015;44:617-23.
    • (2015) Drug Metab Dispos , vol.44 , pp. 617-623
    • Kraynov, E.1    Kamath, A.V.2    Walles, M.3    Tarcsa, E.4    Deslandes, A.5    Iyer, R.A.6
  • 9
    • 84855577639 scopus 로고    scopus 로고
    • Practical theoretic guidance for the design of tumor-Targeting agents
    • Wittrup KD, Thurber GM, Schmidt MM, Rhoden JJ. Practical theoretic guidance for the design of tumor-Targeting agents. Methods Enzymol 2012;503:255-68.
    • (2012) Methods Enzymol , vol.503 , pp. 255-268
    • Wittrup, K.D.1    Thurber, G.M.2    Schmidt, M.M.3    Rhoden, J.J.4
  • 11
    • 0034000453 scopus 로고    scopus 로고
    • Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review
    • MaedaH, Wu J, Sawa T, Matsumura Y, Hori K.Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J Control Release 2000;65:271-84.
    • (2000) J Control Release , vol.65 , pp. 271-284
    • Maedah Wu, J.1    Sawa, T.2    Matsumura, Y.3    Hori, K.4
  • 12
    • 34247391483 scopus 로고    scopus 로고
    • Multiple paths to a drug resistance phenotype: Mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs
    • Fojo T. Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. Drug Resist Updat 2007;10:59-67.
    • (2007) Drug Resist Updat , vol.10 , pp. 59-67
    • Fojo, T.1
  • 14
    • 84890018871 scopus 로고    scopus 로고
    • Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer
    • Gainor JF, Shaw AT. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol 2013;31:3987-96.
    • (2013) J Clin Oncol , vol.31 , pp. 3987-3996
    • Gainor, J.F.1    Shaw, A.T.2
  • 16
    • 33644977169 scopus 로고    scopus 로고
    • Paclitaxelresistant cells have a mutation in the paclitaxel-binding region of betatubulin (Asp26Glu) and less stable microtubules
    • Hari M, Loganzo F, Annable T, Tan X, Musto S, Morilla DB, et al. Paclitaxelresistant cells have a mutation in the paclitaxel-binding region of betatubulin (Asp26Glu) and less stable microtubules. Mol Cancer Ther 2006;5:270-8.
    • (2006) Mol Cancer Ther , vol.5 , pp. 270-278
    • Hari, M.1    Loganzo, F.2    Annable, T.3    Tan, X.4    Musto, S.5    Morilla, D.B.6
  • 17
    • 7444224866 scopus 로고    scopus 로고
    • Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha-or beta-Tubulin and increased microtubule stability
    • Poruchynsky MS, Kim JH, Nogales E, Annable T, Loganzo F, Greenberger LM, et al. Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha-or beta-Tubulin and increased microtubule stability. Biochemistry 2004;43:13944-54.
    • (2004) Biochemistry , vol.43 , pp. 13944-13954
    • Poruchynsky, M.S.1    Kim, J.H.2    Nogales, E.3    Annable, T.4    Loganzo, F.5    Greenberger, L.M.6
  • 18
    • 77649191871 scopus 로고    scopus 로고
    • Microtubules and resistance to tubulin-binding agents
    • Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 2010;10:194-204.
    • (2010) Nat Rev Cancer , vol.10 , pp. 194-204
    • Kavallaris, M.1
  • 20
    • 0025901097 scopus 로고
    • Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide
    • Bugg BY, Danks MK, Beck WT, Suttle DP. Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide. Proc Natl Acad Sci U S A 1991;88:7654-8.
    • (1991) Proc Natl Acad Sci U S A , vol.88 , pp. 7654-7658
    • Bugg, B.Y.1    Danks, M.K.2    Beck, W.T.3    Suttle, D.P.4
  • 21
    • 0036830256 scopus 로고    scopus 로고
    • Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells
    • Grunwald V, DeGraffenried L, Russel D, Friedrichs WE, Ray RB, Hidalgo M. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 2002;62:6141-5.
    • (2002) Cancer Res , vol.62 , pp. 6141-6145
    • Grunwald, V.1    DeGraffenried, L.2    Russel, D.3    Friedrichs, W.E.4    Ray, R.B.5    Hidalgo, M.6
  • 23
    • 84980367693 scopus 로고    scopus 로고
    • Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics
    • Wijdeven RH, Pang B, Assaraf YG, Neefjes J. Old drugs, novel ways out: drug resistance toward cytotoxic chemotherapeutics. Drug Res Updat 2016;28: 65-81.
    • (2016) Drug Res Updat , vol.28 , pp. 65-81
    • Wijdeven, R.H.1    Pang, B.2    Assaraf, Y.G.3    Neefjes, J.4
  • 26
    • 84942114899 scopus 로고    scopus 로고
    • CD30 downregulation MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin
    • Chen R, Hou J, Newman E, Kim Y, Donohue C, Liu X, et al. CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin. Mol Cancer Ther 2015;14: 1376-84.
    • (2015) Mol Cancer Ther , vol.14 , pp. 1376-1384
    • Chen, R.1    Hou, J.2    Newman, E.3    Kim, Y.4    Donohue, C.5    Liu, X.6
  • 27
    • 84941656661 scopus 로고    scopus 로고
    • Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments
    • Loganzo F, Tan X, Sung M, Jin G, Myers JS, Melamud E, et al. Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments. Mol Cancer Ther 2015;14:952-63.
    • (2015) Mol Cancer Ther , vol.14 , pp. 952-963
    • Loganzo, F.1    Tan, X.2    Sung, M.3    Jin, G.4    Myers, J.S.5    Melamud, E.6
  • 28
    • 0025688250 scopus 로고
    • Vivo selection of human tumor cells resistant to monoclonal antibody-Vinca alkaloid immunoconjugates
    • Starling JJ, Maciak RS, Hinson NA, Hoskins J, Laguzza BC, Gadski RA, et al. In vivo selection of human tumor cells resistant to monoclonal antibody-Vinca alkaloid immunoconjugates. Cancer Res 1990;50: 7634-40.
    • (1990) Cancer Res , vol.50 , pp. 7634-7640
    • Starling, J.J.1    Maciak, R.S.2    Hinson, N.A.3    Hoskins, J.4    Laguzza, B.C.5    Gadski, R.A.6
  • 29
    • 84942905381 scopus 로고    scopus 로고
    • A novel anti-CD22 anthracycline-based antibody-drug conjugate (ADC) that overcomes resistance to auristatin-based ADCs
    • Yu SF, Zheng B, Go M, Lau J, Spencer S, Raab H, et al. A novel anti-CD22 anthracycline-based antibody-drug conjugate (ADC) that overcomes resistance to auristatin-based ADCs. Clin Cancer Res 2015;21:3298-306.
    • (2015) Clin Cancer Res , vol.21 , pp. 3298-3306
    • Yu, S.F.1    Zheng, B.2    Go, M.3    Lau, J.4    Spencer, S.5    Raab, H.6
  • 30
    • 84958768935 scopus 로고    scopus 로고
    • A biparatopic HER2-Targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-Targeted therapy
    • Li JY, Perry SR, Muniz-Medina V, Wang X, Wetzel LK, Rebelatto MC, et al. A biparatopic HER2-Targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-Targeted therapy. Cancer Cell 2016;29:117-29.
    • (2016) Cancer Cell , vol.29 , pp. 117-129
    • Li, J.Y.1    Perry, S.R.2    Muniz-Medina, V.3    Wang, X.4    Wetzel, L.K.5    Rebelatto, M.C.6
  • 32
    • 12344302247 scopus 로고    scopus 로고
    • Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer
    • Tanner M, Kapanen AI, Junttila T, Raheem O, Grenman S, Elo J, et al. Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol Cancer Ther 2004;3:1585-92.
    • (2004) Mol Cancer Ther , vol.3 , pp. 1585-1592
    • Tanner, M.1    Kapanen, A.I.2    Junttila, T.3    Raheem, O.4    Grenman, S.5    Elo, J.6
  • 33
    • 84860389569 scopus 로고    scopus 로고
    • Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo
    • Barok M, Tanner M, Koninki K, Isola J. Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. Breast Cancer Res 2011;13:R46.
    • (2011) Breast Cancer Res , vol.13 , pp. R46
    • Barok, M.1    Tanner, M.2    Koninki, K.3    Isola, J.4
  • 34
    • 85008396460 scopus 로고    scopus 로고
    • Emergingmechanisms of resistance to antibody drug conjugates in preclinical models
    • Feb 18; San Francisco, CA: Molecular Med Tri-Con
    • Loganzo F, Sung M, Tan X, Gerber HP. Emergingmechanisms of resistance to antibody drug conjugates in preclinical models. MolecularMed Tri-Con; 2015 Feb 18; San Francisco, CA: Molecular Med Tri-Con.
    • (2015) MolecularMed Tri-Con
    • Loganzo, F.1    Sung, M.2    Tan, X.3    Gerber, H.P.4
  • 35
    • 73949135792 scopus 로고    scopus 로고
    • Mechanisms of multidrug resistance in cancer
    • Gillet JP, Gottesman MM. Mechanisms of multidrug resistance in cancer. Methods Mol Biol 2010;596:47-76.
    • (2010) Methods Mol Biol , vol.596 , pp. 47-76
    • Gillet, J.P.1    Gottesman, M.M.2
  • 37
    • 84922269141 scopus 로고    scopus 로고
    • Antibody-Targeted drugs and drug resistance-challenges and solutions
    • Shefet-Carasso L, Benhar I. Antibody-Targeted drugs and drug resistance-challenges and solutions. Drug Resist Updat 2015;18:36-46.
    • (2015) Drug Resist Updat , vol.18 , pp. 36-46
    • Shefet-Carasso, L.1    Benhar, I.2
  • 38
    • 34248338806 scopus 로고    scopus 로고
    • CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy
    • Walter RB, Gooley TA, van der Velden VH, Loken MR, van Dongen JJ, Flowers DA, et al. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood 2007;109:4168-70.
    • (2007) Blood , vol.109 , pp. 4168-4170
    • Walter, R.B.1    Gooley, T.A.2    Van Der Velden, V.H.3    Loken, M.R.4    Van Dongen, J.J.5    Flowers, D.A.6
  • 39
    • 78651378808 scopus 로고    scopus 로고
    • Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: Mechanisms of action and resistance, safety and efficacy
    • Breccia M, Lo-Coco F. Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy. Expert Opin Biol Ther 2011;11:225-34.
    • (2011) Expert Opin Biol Ther , vol.11 , pp. 225-234
    • Breccia, M.1    Lo-Coco, F.2
  • 40
    • 84881342420 scopus 로고    scopus 로고
    • The biology of MDR1-P-glycoprotein (MDR1-Pgp) in designing functional antibody drug conjugates (ADCs): The experience of gemtuzumab ozogamicin
    • Cianfriglia M. The biology of MDR1-P-glycoprotein (MDR1-Pgp) in designing functional antibody drug conjugates (ADCs): The experience of gemtuzumab ozogamicin. Ann Ist Super Sanita 2013;49:150-68.
    • (2013) Ann Ist Super Sanita , vol.49 , pp. 150-168
    • Cianfriglia, M.1
  • 43
    • 67650733509 scopus 로고    scopus 로고
    • P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients
    • Tang R, Cohen S, Perrot JY, Faussat AM, Zuany-Amorim C, Marjanovic Z, et al. P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients. BMC Cancer 2009;9:199.
    • (2009) BMC Cancer , vol.9 , pp. 199
    • Tang, R.1    Cohen, S.2    Perrot, J.Y.3    Faussat, A.M.4    Zuany-Amorim, C.5    Marjanovic, Z.6
  • 44
    • 84896776546 scopus 로고    scopus 로고
    • Trastuzumab emtansine: Mechanisms of action and drug resistance
    • Barok M, Joensuu H, Isola J. Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res 2014;16:R22.
    • (2014) Breast Cancer Res , vol.16 , pp. R22
    • Barok, M.1    Joensuu, H.2    Isola, J.3
  • 45
    • 84865749390 scopus 로고    scopus 로고
    • Persistence of CD30 expression in Hodgkin lymphoma following brentuximab vedotin (SGN-35) treatment failure
    • Nathwani N, Krishnan AY, Huang Q, Kim Y, Karanes C, Smith EP, et al. Persistence of CD30 expression in Hodgkin lymphoma following brentuximab vedotin (SGN-35) treatment failure. Leuk Lymphoma 2012;53: 2051-3.
    • (2012) Leuk Lymphoma , vol.53 , pp. 2051-2053
    • Nathwani, N.1    Krishnan, A.Y.2    Huang, Q.3    Kim, Y.4    Karanes, C.5    Smith, E.P.6
  • 46
    • 84987754704 scopus 로고    scopus 로고
    • Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: A novel finding
    • Aug 17. [Epub ahead of print]
    • Al-Rohil RN, Torres-Cabala CA, Patel A, Tetzlaff MT, Ivan D, Nagarajan P, et al. Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: A novel finding. J Cutan Pathol. 2016 Aug 17. [Epub ahead of print].
    • (2016) J Cutan Pathol
    • Al-Rohil, R.N.1    Torres-Cabala, C.A.2    Patel, A.3    Tetzlaff, M.T.4    Ivan, D.5    Nagarajan, P.6
  • 47
    • 84887068994 scopus 로고    scopus 로고
    • Targeting HER2+ breast cancer cells: Lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles
    • Owen SC, Patel N, Logie J, Pan G, Persson H, Moffat J, et al. Targeting HER2+ breast cancer cells: lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles. J Control Release 2013;172:395-404.
    • (2013) J Control Release , vol.172 , pp. 395-404
    • Owen, S.C.1    Patel, N.2    Logie, J.3    Pan, G.4    Persson, H.5    Moffat, J.6
  • 48
    • 33744537358 scopus 로고    scopus 로고
    • Lysosomal trafficking and cysteine proteasemetabolism confer targetspecific cytotoxicity by peptide-linked anti-CD30-Auristatin conjugates
    • Sutherland MS, Sanderson RJ, Gordon KA, Andreyka J, Cerveny CG, Yu C, et al. Lysosomal trafficking and cysteine proteasemetabolism confer targetspecific cytotoxicity by peptide-linked anti-CD30-Auristatin conjugates. J Biol Chem 2006;281:10540-7.
    • (2006) J Biol Chem , vol.281 , pp. 10540-10547
    • Sutherland, M.S.1    Sanderson, R.J.2    Gordon, K.A.3    Andreyka, J.4    Cerveny, C.G.5    Yu, C.6
  • 50
    • 33746095034 scopus 로고    scopus 로고
    • Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin/p97
    • Smith LM, Nesterova A, Alley SC, Torgov MY, Carter PJ. Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin/p97. Mol Cancer Ther 2006;5:1474-82.
    • (2006) Mol Cancer Ther , vol.5 , pp. 1474-1482
    • Smith, L.M.1    Nesterova, A.2    Alley, S.C.3    Torgov, M.Y.4    Carter, P.J.5
  • 52
    • 0035017308 scopus 로고    scopus 로고
    • Caveolar endocytosis of simian virus 40 reveals a new two-step vesicular-Transport pathway to the ER
    • Pelkmans L, Kartenbeck J, Helenius A.Caveolar endocytosis of simian virus 40 reveals a new two-step vesicular-Transport pathway to the ER. Nat Cell Biol 2001;3:473-83.
    • (2001) Nat Cell Biol , vol.3 , pp. 473-483
    • Pelkmans, L.1    Kartenbeck, J.2    Helenius, A.3
  • 53
    • 84940486817 scopus 로고    scopus 로고
    • Caveolin-1 dependent endocytosis enhances the chemosensitivity of HER-2 positive breast cancer cells to trastuzumab emtansine (T-DM1)
    • Chung YC, Kuo JF, Wei WC, Chang KJ, Chao WT. Caveolin-1 dependent endocytosis enhances the chemosensitivity of HER-2 positive breast cancer cells to trastuzumab emtansine (T-DM1). PLoS ONE 2015;10:e0133072.
    • (2015) PLoS ONE , vol.10 , pp. e0133072
    • Chung, Y.C.1    Kuo, J.F.2    Wei, W.C.3    Chang, K.J.4    Chao, W.T.5
  • 54
    • 56449129810 scopus 로고    scopus 로고
    • Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate
    • Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008;68:9280-90.
    • (2008) Cancer Res , vol.68 , pp. 9280-9290
    • Lewis Phillips, G.D.1    Li, G.2    Dugger, D.L.3    Crocker, L.M.4    Parsons, K.L.5    Mai, E.6
  • 55
    • 31544441685 scopus 로고    scopus 로고
    • Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: Effects of linker technology on efficacy and toxicity
    • Doronina SO, Mendelsohn BA, Bovee TD, Cerveny CG, Alley SC, Meyer DL, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem 2006;17:114-24.
    • (2006) Bioconjug Chem , vol.17 , pp. 114-124
    • Doronina, S.O.1    Mendelsohn, B.A.2    Bovee, T.D.3    Cerveny, C.G.4    Alley, S.C.5    Meyer, D.L.6
  • 56
    • 79959700509 scopus 로고    scopus 로고
    • Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
    • Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 2011;128:347-56.
    • (2011) Breast Cancer Res Treat , vol.128 , pp. 347-356
    • Junttila, T.T.1    Li, G.2    Parsons, K.3    Phillips, G.L.4    Sliwkowski, M.X.5
  • 57
    • 84955450087 scopus 로고    scopus 로고
    • SLC46A3 is required to transport catabolites of noncleavable antibody maytansine conjugates from the lysosome to the cytoplasm
    • Hamblett KJ, Jacob AP, Gurgel JL, Tometsko ME, Rock BM, Patel SK, et al. SLC46A3 is required to transport catabolites of noncleavable antibody maytansine conjugates from the lysosome to the cytoplasm. Cancer Res 2015;75:5329-40.
    • (2015) Cancer Res , vol.75 , pp. 5329-5340
    • Hamblett, K.J.1    Jacob, A.P.2    Gurgel, J.L.3    Tometsko, M.E.4    Rock, B.M.5    Patel, S.K.6
  • 58
    • 74849117382 scopus 로고    scopus 로고
    • Both t-Darpp and DARPP-32 can cause resistance to trastuzumab in breast cancer cells and are frequently expressed in primary breast cancers
    • Hamel S, Bouchard A, Ferrario C, Hassan S, Aguilar-Mahecha A, Buchanan M, et al. Both t-Darpp and DARPP-32 can cause resistance to trastuzumab in breast cancer cells and are frequently expressed in primary breast cancers. Breast Cancer Res Treat 2010;120:47-57.
    • (2010) Breast Cancer Res Treat , vol.120 , pp. 47-57
    • Hamel, S.1    Bouchard, A.2    Ferrario, C.3    Hassan, S.4    Aguilar-Mahecha, A.5    Buchanan, M.6
  • 59
    • 70149109569 scopus 로고    scopus 로고
    • Novel mechanismof lapatinib resistance in HER2-positive breast tumor cells: Activation of AXL
    • Liu L, Greger J, Shi H, Liu Y, Greshock J, Annan R, et al. Novel mechanismof lapatinib resistance in HER2-positive breast tumor cells: Activation of AXL. Cancer Res 2009;69:6871-8.
    • (2009) Cancer Res , vol.69 , pp. 6871-6878
    • Liu, L.1    Greger, J.2    Shi, H.3    Liu, Y.4    Greshock, J.5    Annan, R.6
  • 60
    • 84892724922 scopus 로고    scopus 로고
    • Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: Critical role for neuregulin blockade in antitumor response to combination therapy
    • Lewis Phillips GD, Fields CT, Li G, Dowbenko D, Schaefer G, Miller K, et al. Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy. Clin Cancer Res 2014;20:456-68.
    • (2014) Clin Cancer Res , vol.20 , pp. 456-468
    • Lewis Phillips, G.D.1    Fields, C.T.2    Li, G.3    Dowbenko, D.4    Schaefer, G.5    Miller, K.6
  • 61
    • 70350494468 scopus 로고    scopus 로고
    • Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma
    • Dornan D, Bennett F, Chen Y, Dennis M, Eaton D, Elkins K, et al. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood 2009;114:2721-9.
    • (2009) Blood , vol.114 , pp. 2721-2729
    • Dornan, D.1    Bennett, F.2    Chen, Y.3    Dennis, M.4    Eaton, D.5    Elkins, K.6
  • 62
    • 5144226211 scopus 로고    scopus 로고
    • PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
    • Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6:117-27.
    • (2004) Cancer Cell , vol.6 , pp. 117-127
    • Nagata, Y.1    Lan, K.H.2    Zhou, X.3    Tan, M.4    Esteva, F.J.5    Sahin, A.A.6
  • 63
    • 84980338826 scopus 로고    scopus 로고
    • Relationship between tumor biomarkers and efficacy in EMILIA, a phase III study of trastuzumab emtansine in HER2-positive metastatic breast cancer
    • Baselga J, Lewis Phillips GD, Verma S, Ro J, Huober J, Guardino E, et al. Relationship between tumor biomarkers and efficacy in EMILIA, a phase III study of trastuzumab emtansine in HER2-positive metastatic breast cancer. Clin Cancer Res 2016;22:3755-63.
    • (2016) Clin Cancer Res , vol.22 , pp. 3755-3763
    • Baselga, J.1    Lewis Phillips, G.D.2    Verma, S.3    Ro, J.4    Huober, J.5    Guardino, E.6
  • 64
    • 84969745074 scopus 로고    scopus 로고
    • Intratumoral payload release influences the potency and bystander-killing effects of antibody-drug conjugates in preclinical models
    • Li F, Emmerton KK, Jonas M, Zhang X, Miyamoto JB, Setter JR, et al. Intratumoral payload release influences the potency and bystander-killing effects of antibody-drug conjugates in preclinical models. Cancer Res 2016;76:2710-9.
    • (2016) Cancer Res , vol.76 , pp. 2710-2719
    • Li, F.1    Emmerton, K.K.2    Jonas, M.3    Zhang, X.4    Miyamoto, J.B.5    Setter, J.R.6
  • 65
    • 84942898855 scopus 로고    scopus 로고
    • Anti-EFNA4 calicheamicin conjugates effectively target triple-negative breast and ovarian tumor-initiating cells to result in sustained tumor regressions
    • Damelin M, Bankovich A, Park A, Aguilar J, Anderson W, Santaguida M, et al. Anti-EFNA4 calicheamicin conjugates effectively target triple-negative breast and ovarian tumor-initiating cells to result in sustained tumor regressions. Clin Cancer Res 2015;21:4165-73.
    • (2015) Clin Cancer Res , vol.21 , pp. 4165-4173
    • Damelin, M.1    Bankovich, A.2    Park, A.3    Aguilar, J.4    Anderson, W.5    Santaguida, M.6
  • 66
    • 84958843614 scopus 로고    scopus 로고
    • Combining antibody-drug conjugates and immune-mediated cancer therapy: What to expect?
    • Gerber HP, Sapra P, Loganzo F, May C. Combining antibody-drug conjugates and immune-mediated cancer therapy: what to expect? Biochem Pharmacol 2016;102:1-6.
    • (2016) Biochem Pharmacol , vol.102 , pp. 1-6
    • Gerber, H.P.1    Sapra, P.2    Loganzo, F.3    May, C.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.